[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.16″ _module_preset=”default” global_module=”3571″ global_colors_info=”{}”][et_pb_fullwidth_header title=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@” subhead=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9kYXRlIiwic2V0dGluZ3MiOnsiYmVmb3JlIjoiIiwiYWZ0ZXIiOiIiLCJkYXRlX2Zvcm1hdCI6ImRlZmF1bHQiLCJjdXN0b21fZGF0ZV9mb3JtYXQiOiI4LzcvMjAyMyJ9fQ==@” text_orientation=”center” background_overlay_color=”RGBA(0,0,0,0)” _builder_version=”4.24.0″ _dynamic_attributes=”title,subhead” _module_preset=”default” title_font=”|700|||||||” title_text_align=”center” title_text_color=”#277099″ title_font_size=”46px” subhead_text_color=”#EFEFEF” subhead_font_size=”20px” subhead_line_height=”1.9em” background_image=”https:\/\/friendsfiduciary.org\/wp-content\/uploads\/ff-main-tout-default.jpg” title_font_size_tablet=”42px” title_font_size_phone=”30px” title_font_size_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Text” _builder_version=”4.25.2″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
For the second proxy season in a row, Friends Fiduciary has filed a shareholder resolution<\/a> at AbbVie asking the Board of Directors to establish and report on a process by which the impact of extended patent exclusivities on product access will be considered in deciding whether to apply for secondary and tertiary patents. Secondary and tertiary patents are the patents applied for following the main, active ingredient patent, and typically cover properties such as methods of administration, manufacturing processes, dosing regimens, and additional indications. These patents can significantly extend the exclusivity period on branded drugs, delaying competition from generic drug makers and resulting in higher drug\/medicine prices for patients, along with increased costs for the U.S. healthcare system. FFC\u2019s proposal does not seek to prohibit AbbVie from applying for secondary and tertiary patents on its medicines; we only ask that the Company disclose the process through which the impact on patient access would be considered when the Company applies for these additional patents.<\/p>\n FFC\u2019s proposal received a 25% vote in support, representing strong support from fellow investors and indicating significant investor concern around this issue.<\/p>\n Our letter to shareholders in support of the proposal can be found here<\/a>.<\/p>\n In addition, the institutional proxy service, ISS, standard policy recommended support for the proposal. Here is their analysis<\/a>.<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#EFEFEF” global_module=”3572″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_nav prev_text=”Previous – %title” next_text=”Next – %title” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_post_nav][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Friends Fiduciary refiles proposal asking company to consider impacts on patient access when applying for patent exclusivities. <\/p>\n","protected":false},"author":14,"featured_media":11333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"